Saturday 10 October 2026
Export all MRK data to Excel Powerpack
Merck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.
145.60
3.22
+2.26%
Follow MRK
Merck & Co., Inc. (MRK) SEC filings, changes and red flags
Red flags
Filings
| Form | Period | Filed | What it reports | Flags |
|---|---|---|---|---|
| 10-Q | Jun 30, 2026 |
P1I2: 25 added · 6 removed · 71 modified P2I1A: no comparison — the Item was not found |
||
| 8-K | Aug 4, 2026 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 8-K | May 26, 2026 | 5.07 Submission of matters to a vote of security holders | ||
| 8-K | May 22, 2026 | 8.01 Other events; 9.01 Financial statements and exhibits | ||
| 10-Q | Mar 31, 2026 | |||
| 8-K | Apr 30, 2026 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 10-K | Dec 31, 2025 |
1: 45 added · 38 removed · 89 modified 1A: 10 added · 3 removed · 60 modified 7: 62 added · 54 removed · 119 modified |
||
| 8-K | Feb 3, 2026 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 8-K | Dec 4, 2025 | 8.01 Other events; 9.01 Financial statements and exhibits | ||
| 10-Q | Sep 30, 2025 | |||
| 8-K | Oct 30, 2025 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 8-K | Sep 9, 2025 | 8.01 Other events; 9.01 Financial statements and exhibits | ||
| 10-Q | Jun 30, 2025 | |||
| 10-K | Dec 31, 2024 |